Aeolus Pharmaceuticals, Inc.

OTCPK:AOLS Stock Report

Market Cap: US$152.0

Aeolus Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Aeolus Pharmaceuticals's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2017

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Aeolus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:AOLS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 171-420
31 Mar 171-420
31 Dec 162-630
30 Sep 162-620
30 Jun 162-520
31 Mar 162-520
31 Dec 152-420
30 Sep 153-320
30 Jun 155-330
31 Mar 1510030
31 Dec 1410030
30 Sep 1410030
30 Jun 148030
31 Mar 144-330
31 Dec 133-830

Quality Earnings: Insufficient data to determine if AOLS has high quality earnings.

Growing Profit Margin: Insufficient data to determine if AOLS's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AOLS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare AOLS's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if AOLS's earnings growth over the past year exceeded the Pharmaceuticals industry average.


Return on Equity

High ROE: AOLS has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies